Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.56 |
| ▸ | BAD | Q92934 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 3/20 | 0.38 |
| ▸ | RXRB | P28702 | 3/20 | 0.38 |
| ▸ | RXRG | P48443 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6570394 | 0.98 | BCL2L1 (0.54) | BCL2L1BADTSHRALDH1A1HTT | |
| SCHEMBL466394 | 0.95 | BCL2L1 (0.50) | BCL2L1BADTSHRALDH1A1HTT | |
| SCHEMBL7444249 | 0.85 | — | — | |
| SCHEMBL10494178 | 0.81 | TSHR (0.44) | BCL2L1BADTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL4974372 | 0.75 | BCL2L1 (0.60) | BCL2L1BADTSHRALDH1A1HTT | |
| SCHEMBL30717272 | 0.73 | BCL2L1 (0.58) | BCL2L1BADTSHRALDH1A1HTT | |
| SCHEMBL598625 | 0.73 | BCL2L1 (0.58) | BCL2L1BADTSHRALDH1A1HTT | |
| SCHEMBL5530397 | 0.73 | BCL2L1 (0.58) | BCL2L1BADTSHRALDH1A1HTT | |
| Bromide SCHEMBL7104246 | 0.73 | BCL2L1 (0.58) | BCL2L1BADTSHRALDH1A1HTT | |
| SCHEMBL6713728 | 0.71 | BCL2L1 (0.56) | BCL2L1BADTSHRALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113874375-A | Cyclic amide compounds and methods thereof for the treatment of rabies | 株式会社大分大学先端医学研究所 | 2021-12-31 | — | — | CN | claimed |
| US-6797700-B2 | ANTICOAGULANTS | AVENTIS PHARMACEUTICALS, INC. | 2004-09-28 | — | — | US | claimed |
| US-6274705-B1 | INHIBIT PLATELET AGGREGATION AND THROMBUS FORMATION, USEFUL IN PREVENTION AND TREATMENT OF THROMBOSIS | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-08-14 | — | — | US | claimed |
| US-5866685-A | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1999-02-02 | — | — | US | claimed |
| CN-113874375-A | Cyclic amide compounds and methods thereof for the treatment of rabies | 株式会社大分大学先端医学研究所 | 2021-12-31 | — | — | CN | disclosed |
| EP-3641776-A1 | ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY | San Diego State University Research Foundation (US) | 2020-04-29 | — | — | EP | disclosed |
| WO-2018237134-A1 | ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2018-12-27 | — | — | WO | disclosed |
| US-20070172422-A1 | Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications | GLAZIER ARNOLD | 2007-07-26 | — | — | US | disclosed |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| US-20030031677-A1 | Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications | DRUG INNOVATION & DESIGN, INCORPORATED | 2003-02-13 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| EP-0848957-A1 | Fas LIGAND SOLUBILIZATION INHIBITOR | KANEBO LTD. (JP) | 1998-06-24 | — | — | EP | disclosed |
| EP-0309766-B1 | N-acylamino acid derivatives and their use | BANYU PHARMA CO LTD (JP) | 1998-04-15 | — | — | EP | disclosed |
| US-5424309-A | Hypotensive agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-06-13 | — | — | US | disclosed |
| US-5122523-A | Hypotensive agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-06-16 | — | — | US | disclosed |
| US-3973033-A | Compositions and methods for producing a vasodilatory effect with a naphthyl tetrahydrofurfuryl amino-ester | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | BCL2L1 1769/4885BAD 56/4885TSHR 3173/4885 |
| US-20030031677-A1 | Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications | EPHA2, EEA1, TPX2 | BCL2L1 2976/4885BAD 2069/4885TSHR 2046/4885 |
| US-20070172422-A1 | Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications | EPHA2, EEA1, HAVCR2 | BCL2L1 3087/4885BAD 2011/4885TSHR 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.